X0508 4 2026-03-11 0001815442 Kymera Therapeutics, Inc. KYMR 0001388406 Chadwick Jeremy G C/O KYMERA THERAPEUTICS, INC. 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 false true false false Chief Operating Officer true Common Stock 2026-03-11 4 M false 20000 43.5 A 93810 D Common Stock 2026-03-11 4 S false 1765 82.1275 D 92045 D Common Stock 2026-03-11 4 S false 12882 83.1013 D 79163 D Common Stock 2026-03-11 4 S false 11111 83.7195 D 68052 D Stock Option (Right to Buy) 43.5 2026-03-11 4 M false 20000 0 D 2034-02-28 Common Stock 20000 60548 D These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.47 to $82.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.47 to $83.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.47 to $84.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. /s/ Bruce Jacobs, as Attorney-in-Fact 2026-03-11